CA
FBLG icon

Clearstead Advisors’s FibroBiologics FBLG Stock Holding History

Clearstead Advisors’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10
Closed -$126 – 3271
2025
Q2 		$126 Buy
+10
New +$180 ﹤0.01% 2596

Other funds holding FBLG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Clearstead Advisors's FBLG Position: Q3 2025 in Review

Clearstead Advisors sold out of FibroBiologics (FBLG) in Q3 2025, closing a stake of 10 shares — an estimated $126 sold.

Clearstead Advisors first reported a position in FBLG in Q2 2025 and held it in 1 quarter. The position peaked at $126 in Q2 2025. 52 funds tracked by Wall St. Rank hold FBLG as of Q3 2025.

  • Clearstead Advisors reported no remaining FibroBiologics position as of Q3 2025 after selling out during the quarter.
  • Clearstead Advisors sold 10 FibroBiologics shares in Q3 2025, an estimated $126.
  • Clearstead Advisors first reported a position in FibroBiologics in Q2 2025 and held it in 1 quarter.
  • Clearstead Advisors's FibroBiologics position peaked at $126 in Q2 2025.
  • 52 funds tracked by Wall St. Rank held FibroBiologics as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.